Kennon

Board of Trustees approves project for Auburn University Gulf Coast Engineering Research Station in Orange Beach

Retrieved on: 
Friday, September 16, 2022
Engineering education, Trustee, University, Agriculture, Department, Dislocation, Auburn University, Gulf of Mexico, Kennon, Department of Conservation and Natural Resources, Conservation, City, Natural Resources, Director, Quality of life, Goal, Solution, Friends, Alabama Gulf Coast Zoo, Board, Water quality, Research, Auburn University College of Architecture, Design, and Construction, Multimedia, Tourism, Oil, Engineering, Gulf Coast of the United States

AUBURN, Ala., Sept. 16, 2022 /PRNewswire/ -- Auburn football isn't the only thing going orange this weekend, as the Board of Trustees approved a project Friday to build an Auburn University Gulf Coast Engineering Research Station in Orange Beach.

Key Points: 
  • AUBURN, Ala., Sept. 16, 2022 /PRNewswire/ -- Auburn football isn't the only thing going orange this weekend, as the Board of Trustees approved a project Friday to build an Auburn University Gulf Coast Engineering Research Station in Orange Beach.
  • The project will provide dedicated space for research of coastal environments and communities of the Gulf Coast, while also providing collaborative opportunities with other Marine Environmental Sciences Consortium institutions.
  • Orange Beach Mayor Tony Kennon said the city is proud to work with Auburn and other universities to create long-term solutions for the state's Gulf Coast, and beyond.
  • Funding for the station was secured through the Alabama Gulf Coast Recovery Council in cooperation with the state's Department of Conservation and Natural Resources.

Kennon Products Releases Revolutionary Suicide Prevention Door for Medical Health Facilities

Retrieved on: 
Wednesday, April 27, 2022
Pressure, CEO, Prison, Suicide, Kennon, Death, Patient, Engineering, Privacy, National Fire Protection Association, Health, Morale, Certification, Industry, Hospital

SHERIDAN, Wyo., April 27, 2022 /PRNewswire/ -- As medical facilities across the US strengthen efforts to make healthcare environments safer, industry pioneer Kennon Products has introduced its second-generation in-room Soft Suicide Prevention Door (SSPD), the Kennon SSPD Door 2.0.

Key Points: 
  • SHERIDAN, Wyo., April 27, 2022 /PRNewswire/ -- As medical facilities across the US strengthen efforts to make healthcare environments safer, industry pioneer Kennon Products has introduced its second-generation in-room Soft Suicide Prevention Door (SSPD), the Kennon SSPD Door 2.0.
  • The Kennon SSPD Door 2.0 is designed to give patients privacy while its ligature-resistant breakaway hinge protects them from harming themselves.
  • The door is ideal for use in behavioral health facilities, psychiatric hospitals, mental health facilities, emergency departments, assisted-living situations, prisons, and juvenile facilities.
  • "The Kennon SSPD Door 2.0 is the most advanced in-room suicide prevention door.

Healthfuse Accelerates High-Growth Plans with Kennon Askew as Senior Vice President

Retrieved on: 
Tuesday, March 9, 2021
Kennon

"Healthfuse works tirelessly to strengthen and protect our hospital partners' financial position so they can focus on their patient communities.

Key Points: 
  • "Healthfuse works tirelessly to strengthen and protect our hospital partners' financial position so they can focus on their patient communities.
  • "I'm thrilled to be a part of the innovative Healthfuse team," says Kennon.
  • Kennon comes to Healthfuse from Ensemble Health Partners, where he served as Vice President of Business Development and Chief Development Officer.
  • Prior to Ensemble Health Partners, Kennon served as Vice President of Business Development at Apex Revenue Technologies.

Odgers Berndtson COO, Kennon Kincaid, Joins Getka's Board of Advisors

Retrieved on: 
Wednesday, January 13, 2021
Odgers, Kennon, Midstream, Articles, Energy

NEW YORK, Jan. 13, 2021 /PRNewswire/ -- Getka Group, a Tulsa-based midstream hydrocarbon operator with extensive pipeline and terminal asset experience in the U.S. and Canada, has appointed Odgers Berndtson U.S.'s Chief Operating Officer, Kennon Kincaid, to its Board of Advisors.

Key Points: 
  • NEW YORK, Jan. 13, 2021 /PRNewswire/ -- Getka Group, a Tulsa-based midstream hydrocarbon operator with extensive pipeline and terminal asset experience in the U.S. and Canada, has appointed Odgers Berndtson U.S.'s Chief Operating Officer, Kennon Kincaid, to its Board of Advisors.
  • "We are thrilled that Kennon will be joining Getka's board of advisors," said Dariusz Cichocki, CEO and President of Getka.
  • As the COO of Odgers Berndtson U.S., Kennon oversees the firm's U.S. operations and is the Co-Head of its U.S. brand extensions: Berwick Partners and Odgers Interim.
  • For more than 50 years, Odgers Berndtson has delivered executive search, leadership assessment, and development strategies to the world's biggest and best organizations.

BioAgilytix Welcomes Kennon Broadhurst as Vice President of Global Marketing to Its Commercial Leadership Team

Retrieved on: 
Tuesday, September 22, 2020
Articles, Life sciences, Kennon, Biosimilar, Commercialization

DURHAM, N.C., Sept. 22, 2020 /PRNewswire/ --BioAgilytix Labs is pleased to announce the appointment of Kennon Broadhurst to its Commercial Leadership team as Vice President of Global Marketing.

Key Points: 
  • DURHAM, N.C., Sept. 22, 2020 /PRNewswire/ --BioAgilytix Labs is pleased to announce the appointment of Kennon Broadhurst to its Commercial Leadership team as Vice President of Global Marketing.
  • Kennon joins BioAgilytix after having more than 26 years of experience in sales, marketing and product commercialization experience within the Pharmaceutical and Biotech industries.
  • Prior to joining BioAgilytix, Kennon served as Managing Partner at the Bilgola Group, which specializes in marketing and product commercialization consulting for the life science industry.
  • Before his role as managing partner, Kennon was Global Marketing Lead for Oncology and Hematology Biosimilars at Amgen.